Génome Québec & Montreal Heart Institute Pharmacogenomics Centre: A translational pharmacogenomics platform - From R&D to the clinic

Pharmacogenomics

Volumn 9, Issue 10, 2008, Pages 1391-1396

  Phillips, Michael S ^a   Hibi, Abdelmadjid K ^a   van Rooij, Tibor ^a   Smith, Andrea C ^a   James, Susan ^a   Marsh, Sharon ^a   Laplante, Nathalie ^a   Dubé, Marie Pierre ^a   Tardif, Jean Claude ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CYTOCHROME P450 2C9; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOXYGENASE INHIBITOR; WARFARIN;

ARTICLE; BIOINFORMATICS; CANADA; CLINICAL LABORATORY; CLINICAL RESEARCH; EVIDENCE BASED MEDICINE; GENETIC MARKER; GENOTYPE; GOOD LABORATORY PRACTICE; HUMAN; INFORMATION SYSTEM; INFORMATION TECHNOLOGY; MUSCLE DISEASE; PHARMACOGENOMICS; QUALITY CONTROL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 55449083194     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.10.1391     Document Type: Article

References (6)

1. Nelson MR, Bacanu SA, Mosteller M et al.: Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J. (2008) (Epub ahead of print).
2. Pirmohamed M, James S, Meakin S et al.: Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329, 15-19 (2004).
3. Swen JJ, Huizinga TW, Gelderblom H et al.: Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med. 4, E209 (2007).
4. Law M, Rudnicka AR: Statin safety: a systematic review. Am. J. Cardiol. 97, C52-C60 (2006).
5. King CR, Porche-Sorbet RM, Cage BF et al.: Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose. Am. J. Clin. Pathol. 129, 876-883 (2008).
6. Gage B, Eby C, Johnson J et al.: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84 (3), 326-331 (2008).